-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 23, Guangdong Sunshine Pharmaceutical submitted a new drug clinical application for class 1 new drug HEC169096 tablets
.
Statistics show that the company and its subsidiaries have earlier approved nearly 30 Class 1 new drugs (including chemical drugs and biological drugs) for clinical trials, of which 3 have entered Phase III clinical trials, involving esophageal squamous cell carcinoma, chronic hepatitis B, Type 2 diabetes and other indications
.
.
Statistics show that the company and its subsidiaries have earlier approved nearly 30 Class 1 new drugs (including chemical drugs and biological drugs) for clinical trials, of which 3 have entered Phase III clinical trials, involving esophageal squamous cell carcinoma, chronic hepatitis B, Type 2 diabetes and other indications
.
Figure 1: The latest product status of Guangdong Dongguang Pharmaceutical Co.
, Ltd.
, Ltd.
Source: CDE official website
Table 1: Class 1 new drugs approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to data from Minet.
com, there are 7 new Class 1 drugs (including 1 biological drug) approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021, involving influenza A, diabetic kidney disease , acute myeloid leukemia, chronic B.
diseases such as hepatitis
.
Up to now, the company has nearly 30 class 1 new drugs approved for clinical use
.
com, there are 7 new Class 1 drugs (including 1 biological drug) approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021, involving influenza A, diabetic kidney disease , acute myeloid leukemia, chronic B.
diseases such as hepatitis
.
Up to now, the company has nearly 30 class 1 new drugs approved for clinical use
.
Table 2: Class 1 new drugs that have entered Phase III clinical trials
Source: Minet China Drug Clinical Trials Publicity Library
Lelotinib mesylate capsules is an EGFR/HER2 inhibitor that can target multiple targets including EGFR (wild type, sensitive mutation, T790M mutation), Her2, Her4, RIPK2, IRAK1, BTK and BLK, and is intended for use in For the treatment of esophageal cancer, as well as the treatment of patients with advanced malignant solid tumors such as pancreatic cancer, head and neck cancer, and non-small cell lung cancer , the new drug is currently undergoing Phase III clinical trials for esophageal squamous cell carcinoma indications
.
.
Mofecidine Mesylate Capsules is a dihydropyrimidine drug.
According to its mechanism of action, it is a targeted HBV nucleocapsid protein assembly inhibitor.
It can reduce the correct assembly of the viral capsid in a dose-dependent manner and accelerate the formation of abnormal capsids.
Thereby, it strongly inhibits the replication of HBV and the production of mature virus particles.
Currently, the phase III clinical trial of the new drug for chronic hepatitis B is in progress
.
According to its mechanism of action, it is a targeted HBV nucleocapsid protein assembly inhibitor.
It can reduce the correct assembly of the viral capsid in a dose-dependent manner and accelerate the formation of abnormal capsids.
Thereby, it strongly inhibits the replication of HBV and the production of mature virus particles.
Currently, the phase III clinical trial of the new drug for chronic hepatitis B is in progress
.
Rongagliflozin Pyroglutamate Capsules is an SGLT2 inhibitor for the treatment of type 2 diabetes, which can increase urinary glucose excretion and lower blood sugar by reducing renal glucose reabsorption and reducing renal glucose threshold.
Phase III clinical trials for type 2 diabetes indications are in progress
.
Phase III clinical trials for type 2 diabetes indications are in progress
.
On February 23, Guangdong Sunshine Pharmaceutical submitted a new drug clinical application for class 1 new drug HEC169096 tablets
.
Statistics show that the company and its subsidiaries have earlier approved nearly 30 Class 1 new drugs (including chemical drugs and biological drugs) for clinical trials, of which 3 have entered Phase III clinical trials, involving esophageal squamous cell carcinoma, chronic hepatitis B, Type 2 diabetes and other indications
.
.
Statistics show that the company and its subsidiaries have earlier approved nearly 30 Class 1 new drugs (including chemical drugs and biological drugs) for clinical trials, of which 3 have entered Phase III clinical trials, involving esophageal squamous cell carcinoma, chronic hepatitis B, Type 2 diabetes and other indications
.
Figure 1: The latest product status of Guangdong Dongguang Pharmaceutical Co.
, Ltd.
, Ltd.
Source: CDE official website
Table 1: Class 1 new drugs approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to data from Minet.
com, there are 7 new Class 1 drugs (including 1 biological drug) approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021, involving influenza A, diabetic kidney disease , acute myeloid leukemia, chronic B.
diseases such as hepatitis
.
Up to now, the company has nearly 30 class 1 new drugs approved for clinical use
.
com, there are 7 new Class 1 drugs (including 1 biological drug) approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021, involving influenza A, diabetic kidney disease , acute myeloid leukemia, chronic B.
diseases such as hepatitis
.
Up to now, the company has nearly 30 class 1 new drugs approved for clinical use
.
Table 2: Class 1 new drugs that have entered Phase III clinical trials
Source: Minet China Drug Clinical Trials Publicity Library
Lelotinib mesylate capsules is an EGFR/HER2 inhibitor that can target multiple targets including EGFR (wild type, sensitive mutation, T790M mutation), Her2, Her4, RIPK2, IRAK1, BTK and BLK, and is intended for use in For the treatment of esophageal cancer, as well as the treatment of patients with advanced malignant solid tumors such as pancreatic cancer, head and neck cancer, and non-small cell lung cancer , the new drug is currently undergoing Phase III clinical trials for esophageal squamous cell carcinoma indications
.
.
Mofecidine Mesylate Capsules is a dihydropyrimidine drug.
According to its mechanism of action, it is a targeted HBV nucleocapsid protein assembly inhibitor.
It can reduce the correct assembly of the viral capsid in a dose-dependent manner and accelerate the formation of abnormal capsids.
Thereby, it strongly inhibits the replication of HBV and the production of mature virus particles.
Currently, the phase III clinical trial of the new drug for chronic hepatitis B is in progress
.
According to its mechanism of action, it is a targeted HBV nucleocapsid protein assembly inhibitor.
It can reduce the correct assembly of the viral capsid in a dose-dependent manner and accelerate the formation of abnormal capsids.
Thereby, it strongly inhibits the replication of HBV and the production of mature virus particles.
Currently, the phase III clinical trial of the new drug for chronic hepatitis B is in progress
.
Rongagliflozin Pyroglutamate Capsules is an SGLT2 inhibitor for the treatment of type 2 diabetes, which can increase urinary glucose excretion and lower blood sugar by reducing renal glucose reabsorption and reducing renal glucose threshold.
Phase III clinical trials for type 2 diabetes indications are in progress
.
Phase III clinical trials for type 2 diabetes indications are in progress
.
On February 23, Guangdong Sunshine Pharmaceutical submitted a new drug clinical application for class 1 new drug HEC169096 tablets
.
Statistics show that the company and its subsidiaries have earlier approved nearly 30 Class 1 new drugs (including chemical drugs and biological drugs) for clinical trials, of which 3 have entered Phase III clinical trials, involving esophageal squamous cell carcinoma, chronic hepatitis B, Type 2 diabetes and other indications
.
.
Statistics show that the company and its subsidiaries have earlier approved nearly 30 Class 1 new drugs (including chemical drugs and biological drugs) for clinical trials, of which 3 have entered Phase III clinical trials, involving esophageal squamous cell carcinoma, chronic hepatitis B, Type 2 diabetes and other indications
.
Figure 1: The latest product status of Guangdong Dongguang Pharmaceutical Co.
, Ltd.
, Ltd.
Source: CDE official website
Table 1: Class 1 new drugs approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to data from Minet.
com, there are 7 new Class 1 drugs (including 1 biological drug) approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021, involving influenza A, diabetic kidney disease , acute myeloid leukemia, chronic B.
diseases such as hepatitis
.
Up to now, the company has nearly 30 class 1 new drugs approved for clinical use
.
disease disease diseasecom, there are 7 new Class 1 drugs (including 1 biological drug) approved for clinical use by Guangdong Sunshine Pharmaceutical and its subsidiaries in 2021, involving influenza A, diabetic kidney disease , acute myeloid leukemia, chronic B.
diseases such as hepatitis
.
Up to now, the company has nearly 30 class 1 new drugs approved for clinical use
.
Table 2: Class 1 new drugs that have entered Phase III clinical trials
Source: Minet China Drug Clinical Trials Publicity Library
Lelotinib mesylate capsules is an EGFR/HER2 inhibitor that can target multiple targets including EGFR (wild type, sensitive mutation, T790M mutation), Her2, Her4, RIPK2, IRAK1, BTK and BLK, and is intended for use in For the treatment of esophageal cancer, as well as the treatment of patients with advanced malignant solid tumors such as pancreatic cancer, head and neck cancer, and non-small cell lung cancer , the new drug is currently undergoing Phase III clinical trials for esophageal squamous cell carcinoma indications
.
tumor tumor tumor.
Mofecidine Mesylate Capsules is a dihydropyrimidine drug.
According to its mechanism of action, it is a targeted HBV nucleocapsid protein assembly inhibitor.
It can reduce the correct assembly of the viral capsid in a dose-dependent manner and accelerate the formation of abnormal capsids.
Thereby, it strongly inhibits the replication of HBV and the production of mature virus particles.
Currently, the phase III clinical trial of the new drug for chronic hepatitis B is in progress
.
According to its mechanism of action, it is a targeted HBV nucleocapsid protein assembly inhibitor.
It can reduce the correct assembly of the viral capsid in a dose-dependent manner and accelerate the formation of abnormal capsids.
Thereby, it strongly inhibits the replication of HBV and the production of mature virus particles.
Currently, the phase III clinical trial of the new drug for chronic hepatitis B is in progress
.
Rongagliflozin Pyroglutamate Capsules is an SGLT2 inhibitor for the treatment of type 2 diabetes, which can increase urinary glucose excretion and lower blood sugar by reducing renal glucose reabsorption and reducing renal glucose threshold.
Phase III clinical trials for type 2 diabetes indications are in progress
.
Phase III clinical trials for type 2 diabetes indications are in progress
.
